// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Durability of 10 kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy 18 Month Multicenter Randomized Controlled Trial Results

Erika Petersen - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic neuropathy

N/A

Effect of Siponimod on Disability Progression as Measured by the Ambulation Score a Subscore of the Neurostatus EDSS Post hoc Analysis of the EXPAND Trial in SPMS

Marcus DSouza - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Siponimod

Efficacy and Safety Outcomes in Patients with Chronic Traumatic Brain Injury Final Analysis of the Phase 2 Stemtra Trial

Peter McAllister - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Traumatic brain injury

SB 623

Estimating long term effect of siponimod on disability progression versus virtual placebo in SPMS using RPSFT model EXPAND data up to 7 years

Bruce Cree - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Siponimod

Evaluation of the Long Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine A Phase 3 40 Week Multicenter Extension to the Advance Trial

Brad Klein - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Migraine

Calcitonin

Factors associated with Influenza vaccination rates among people with Multiple Sclerosis

Mariana Gaviria - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

HELIOS A Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin Mediated Amyloidosis with Polyneuropathy

David Adams - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Peripheral neuropathy

Patisiran

Impact of Multiple Sclerosis Disease Modifying Therapies on Effectiveness of SARS Cov 2 Vaccines A Longitudinal Total Population Study of National Health Service NHS England

Afagh Garjani - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

glatiramer

A Novel Application of SRTR Data to Interrogate the Effects of HLA-DQ Mismatches in Kidney Transplantation

D. Isaacson - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Randomised Trial Of Normothermic Machine Perfusion Versus Static Cold Storage In Donation After Circulatory Death Renal Transplantation

S. Hosgood - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Transplant rejection

N/A

A Single-Centre Study on the Diagnosis and Management of Transplant Ureteric Strictures: An 11 Year Experience

W. G. Norton - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An Analysis of Serological Response and Infection Outcomes Following Oxford Astra-Zeneca (azd1222) and Pfizer-Biontech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Pancreas Transplant Patients

A. Asderakis - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

An International Multi-Institutional Comparison of Liver Transplantation for Hepatocellular Carcinoma: United States, United Kingdom, and Canada

T. Ivanics - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Liver cancer

N/A

Anti-Fibrotic Property of Adipose Derived Regenerative Cells on Hydrogen Peroxide Induced Injury in Nrk-52e Cells

R. Chawangwongsanukun - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydrogen peroxide

Characterisation of Kidney-Specific Extracellular Vesicles During Isolated Organ Normothermic Machine Perfusion

J. Ashcroft - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Chimeric Antigen Receptor Regulatory T Cells (CAR-Tregs) Provide Significantly Greater Modulation of Alloimmune Responses Than Alternative Alloantigen-Specific Treg Strategies

A. S. Kurt - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

2D10

CT Based Iliac Vessel Calcification Scoring: Long Term Patient and Allograft Outcomes

L. Clementoni - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Decision-Making Among HCV-Negative Transplant Candidates Offered Organs from Donors with HCV Infection

E. Schnellinger - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Defining the Longitudinal Dynamics of Immune Cells in Blood in the First Year After Pediatric Liver Transplantation (pLTx)

E. Chichelnitskiy - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Development of Diagnostic Algorithms for Peri-Operative Error Cause and Effect Analysis in Renal Transplant Surgery

P. Gogalniceanu - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved